New hope for kids with arthritis: Long-Term drug study now recruiting

NCT ID NCT07553182

Recruiting now Disease control Sponsor: Alfasigma S.p.A. Source: ClinicalTrials.gov ↗

First seen May 07, 2026 · Last updated May 07, 2026

Summary

This study looks at the long-term safety and effectiveness of the drug filgotinib in children and teens (ages 8 to 17) with juvenile idiopathic arthritis (JIA). Participants must have already completed a prior filgotinib study and shown improvement. The goal is to see if the drug continues to control disease activity over time and to monitor any side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for JUVENILE IDIOPATHIC ARTHRITIS (JIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Asklepios Klinik Sankt Augustin GmbH
NOT_YET_RECRUITING

Sankt Augustin, 53757, Germany

Contact
Bicetre Hospital
NOT_YET_RECRUITING

Le Kremlin-Bicêtre, 94270, France

Contact
Great Ormond Street Hospital for Children
NOT_YET_RECRUITING

London, WC1N 3JH, United Kingdom

Contact
Hamburger Zentrum für Kinder- und Jugendrheumatologie
RECRUITING

Hamburg, 22081, Germany

Contact

Conditions

Explore the condition pages connected to this study.

JUVENILE IDIOPATHIC ARTHRITIS (JIA)